Preclinical models of infectious diseases
Ended Awarded Last action
- Contract number
- 75N93024F00001
- Awardee
-
University Of Texas Medical Branch At Galveston UEI MSPWVMXXMN76
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,199,853
Award facts
- Contract value 69% obligated
-
- $1,199,853.00 Current, with exercised options
- $1,745,363.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Galveston, TX 77555, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $272,755 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $109,647 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $817,451 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.745 million delivery order to the University of Texas Medical Branch at Galveston (UTMB) on April 15, 2024, for the establishment of a small animal model of Nipah virus (NIV) infection to support the assessment of medical countermeasures efficacy. This cost-no-fee delivery order is scheduled for completion by April 14, 2026, and represents work performed under NIAID's Preclinical Models of Infectious Diseases parent contract vehicle spanning 2017–2024. The award carries no set-aside designation, reflecting the specialized and unique nature of UTMB's high-containment laboratory capabilities and expertise in infectious disease research. Work will be performed at UTMB's Galveston, Texas facility, which maintains extensive biosafety level 3 and 4 laboratory infrastructure critical to federal pandemic preparedness initiatives.
This delivery order exemplifies UTMB's established role as a premier national resource for preclinical infectious disease research and medical countermeasure development. The institution operates under a single-award Basic Ordering Agreement with the Bureau of Medicine and Surgery valued at $146.3 million for comprehensive preclinical testing services, with prior task orders supporting the development of small animal and non-human primate models for agents including Lassa virus, cytomegalovirus, herpes simplex virus, and biosafety level 4 pathogens. The Nipah virus animal model development supports the federal government's strategic objectives in evaluating vaccines and therapeutics against high-consequence biological threats and emerging zoonotic pathogens of significant public health concern.
Quick answers
Who was awarded contract 75N93024F00001?
75N93024F00001 was awarded to University Of Texas Medical Branch At Galveston by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 15, 2024.
How much is contract 75N93024F00001 worth?
The government has obligated $1,199,853 on 75N93024F00001. Its potential value, with all options, is $1,745,363.
Is contract 75N93024F00001 an order under another contract?
Yes. 75N93024F00001 is a delivery order under HHSN272201700040I, an indefinite delivery contract, on NIAID Preclinical Models of Infectious Diseases 2017-2024.
Was contract 75N93024F00001 competed?
The extent of competition for 75N93024F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award